The DOI matches its Crossref record; 89 of the 90 references it cites were found in a registry or an index.
Pro-Resolving Lipid Mediators Improve Neuronal Survival and Increase Aβ42 Phagocytosis
Open accessAbstract
Inflammation in the brain is a prominent feature in Alzheimer's disease (AD). Recent studies suggest that chronic inflammation can be a consequence of failure to resolve the inflammation. Resolution of inflammation is mediated by a family of lipid mediators (LMs), and the levels of these specialized pro-resolving mediators (SPMs) are reduced in the hippocampus of those with AD. In the present study, we combined analysis of LMs in the entorhinal cortex (ENT) from AD patients with in vitro analysis of their direct effects on neurons and microglia. We probed ENT, an area affected early in AD pathogenesis, by liquid chromatography-tandem mass spectrometry (LC-MS-MS), and found that the levels of the SPMs maresin 1 (MaR1), protectin D1 (PD1), and resolvin (Rv) D5, were lower in ENT of AD patients as compared to age-matched controls, while levels of the pro-inflammatory prostaglandin D2 (PGD2) were higher in AD. In vitro studies showed that lipoxin A4 (LXA4), MaR1, resolvin D1 (RvD1), and protectin DX (PDX) exerted neuroprotective activity, and that MaR1 and RvD1 down-regulated β-amyloid (Aβ)42-induced inflammation in human microglia. MaR1 exerted a stimulatory effect on microglial uptake of Aβ42. Our findings give further evidence for a disturbance of the resolution pathway in AD, and indicate that stimulating this pathway is a promising treatment strategy for AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In vitro and in vivo studies suggested that MaR1 can inhibit inflammation and promote phagocytosis in microglia428,430,431 and improve the cognitive decline in AD mouse model.432”
From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [428]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Liquid chromatography-tandem mass spectrometry (LC-MS-MS) analysis of lipid mediators in the entorhinal cortex of AD patients revealed the downregulation of SPMs including protectin D1 (PD1), maresin 1 (MaR1) and resolvin (RvD5), and upregulation of PGD2, a proinflammatory lipid mediator, compared with age-matched controls.428”
From Role of neuroinflammation in neurodegeneration development (2023) · cites this paper as [428]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Xu, M., Tan, B., Zhou, W., Wei, T., Lai, W., Tan, J., & Dong, J. (2013) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12069 · Cited by 51
RetractedAlzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484
Cytokine-mediated regulation of CXCR4 expression in human neutrophils
Nagase, H., Miyamasu, M., Yamaguchi, M., Imanishi, M., Tsuno, N. H., Matsushima, K., Yamamoto, K., Morita, Y., & Hirai, K. (2002) · Journal of Leukocyte Biology · doi:10.1189/jlb.71.4.711 · Cited by 4,713
Pro-resolving lipid mediators are leads for resolution physiology
Serhan, C. N. (2014) · Nature · doi:10.1038/nature13479 · Cited by 3,041
Self-citationOxidative stress hypothesis in Alzheimer’s disease
Markesbery, W. R. (1997) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(96)00629-6 · Cited by 2,383
Leukotrienes and Lipoxins: Structures, Biosynthesis, and Biological Effects
Samuelsson, B. O., Dahlén, S., LINDGREN, J. Å., Rouzer, C. A., & Serhan, C. N. (1987) · Science · doi:10.1126/science.2820055 · Cited by 2,233
Self-citationBrain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease.
Griffin, W. S., Stanley, L. C., Ling, C., White, L., MacLeod, V, Perrot, L. J., White, C. L., & Araoz, C. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.19.7611 · Cited by 1,777
Polyunsaturated fatty acids and their metabolites in brain function and disease
Bazinet, R. P., & Layé, S. (2014) · Nature reviews. Neuroscience · doi:10.1038/nrn3820 · Cited by 1,694
Serhan, C. N., Hong, S., Gronert, K., Colgan, S. P., Devchand, P. R., Mirick, G., & Moussignac, R.-L. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020760 · Cited by 1,650
Self-citationMcGeer, P. L., Schulzer, M., & McGeer, E. G. (1996) · Neurology · doi:10.1212/wnl.47.2.425 · Cited by 1,367
Cited by
Sorted by citations
Items 201–212 of 212
Oméga 3 et troubles de l'humeur : mécanismes d'actions neuroprotecteurs
Martinat, M. (2022) · theses.fr (ABES) · doi:10.70675/6f114f20z6c83z41a1zaa52zb4bae73f6832
Effets des oméga-3 et de leurs dérivés oxygénés dans le diabète de type 2
Legroux, I. (2024) · theses.fr (ABES) · doi:10.70675/b865e951z5bdfz4cfaz8162z25ab321cfd7b
Wang, S., Lu, W., Ge, L., Wu, H., Wu, J., Cheng, K., Xiao, H., Wang, X., Huang, F., Wang, S., et al. (2026) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2026.2649917
Self-citationKailash, S., Gokulavani, L., Pandi Prabha, S., & Karthik, C. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-11929-1
Kim, D., Kim, Y. S., & Jeong, B. (2026) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1002/trc2.70288
Christifano, D. N., Kelly, E., Sands, S. A., Honea, R. A., Morris, J. K., Burns, J. M., & Taylor, M. K. (2026) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2026.102762
McDermott, C., Moreno, J. A., Nordgren, T., Schenkel, A., & Schaeffer, J. (2026) · doi:10.25675/3.027509
Serhan, C. N. (2026) · Current topics in microbiology and immunology · doi:10.1007/82_2026_354
Self-citationLozano, R., Lin, X., Hagerman, R., Martínez‐Cerdeño, V., & Pinto, D. (2026) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2026.1932396
Fan, D., Zhai, W., Zhang, Q., Li, J., Wang, Y., & Sun, L. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261499707
Brain insulin resistance and microglial immunometabolic dysregulation in neurodegenerative diseases
Liu, X., Zhang, X., Su, Y., Guan, G., Luo, X., & Zhang, P. (2026) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2026.2002283
Microglia: Metabolic Adaptation in Neurodegeneration
Aljayousi, L., Gentile, N., & Ayata, P. (2026) · The Neuroscientist · doi:10.1177/10738584261498171
Metadata
- Authors
- Zhu, M., Wang, X., Hjorth, E., Colas, R. A., Schroeder, L., Granholm, A.-C., Serhan, C. N., & Schultzberg, M.
- Affiliations
- Karolinska Institutet (SE)
- Shanghai Jiao Tong University (CN)
- Brigham and Women's Hospital (US)
- Medical University of South Carolina (US)
- Corresponding author
- Schultzberg, Marianne
- Venue
- Molecular Neurobiology
- Published
- 2015-12-09
- Volume
- 53
- Issue
- 4
- Pages
- 2733-2749
- ISSN
- 0893-7648 (ISSN-L)
- 1559-1182
- PMC
- PMC4824659
- OpenAlex
- W2291813090
- Cited by
- 204
- References
- 90
- Citations by year
- 2026: 14 · 2025: 10 · 2024: 22 · 2023: 21 · 2022: 25 · 2021: 26 · 2020: 20 · 2019: 21 · 2018: 19 · 2017: 20 · 2016: 6
- FWCI
- 14.46
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Molecular Neurobiology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- The Swedish Research Council (22743 and 22744)
- The Chinese Scholarship Council
- Swedish Brain Power
- The Knut and Alice Wallenberg Foundation
- Karolinska Institutet research funds
- The Swedish Alzheimer Foundation
- Stiftelsen för Gamla Tjänarinnor
- Gun och Bertil Stohnes Stiftelse
- Barmore Fund
- National Institutes of Health (P01GM095467, GM038765)
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, inflammation resolution, specialized pro-resolving mediators, lipid mediators, entorhinal cortex, maresin 1, protectin D1, resolvin D1, lipoxin A4, protectin DX, resolvin D5, prostaglandin D2, microglia, amyloid-beta 42, phagocytosis, neuroprotection, neuroinflammation
- MeSH terms
- Aged, Cell Survival, Chromatography, Liquid, Female, Humans, Lipids, Male, Neurons, Peptide Fragments, Phagocytosis, Phenotype, Postmortem Changes, Amyloid beta-Peptides, Microglia, Entorhinal Cortex, Staurosporine, Cell Line, Tumor, Tandem Mass Spectrometry
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
